DHL Group—capitalizing off the momentum garnered from the LAX cold storage project—is expanding its dedicated airfreight cold chain network, aimed at strengthening global logistics for temperature-sensitive pharmaceutical products, vaccines, and advanced therapies.

This initiative includes the introduction of a dedicated Boeing 777 freighter on key routes and expanded cold-chain connectivity between major hubs, reflecting the logistics industry’s focus on supporting complex life sciences and healthcare supply chains.¹

The network forms part of DHL’s broader investment in health logistics, a sector brand created to consolidate its life sciences and healthcare (LSH) services. This expansion responds to evolving industry needs, such as increased demand for biologics, cell and gene therapies, and high-value pharmaceuticals that require precise temperature control and regulatory compliance during transport.²

Why are cold chain networks critical for pharma supply chains?

Temperature-controlled logistics is a core component of pharmaceutical supply chains because many biologics, vaccines, and specialized therapeutics are sensitive to heat, cold, or temperature fluctuations. Cold chain breaches can compromise product integrity, leading to efficacy loss or regulatory non-compliance. Real-time environmental monitoring and good distribution practice (GDP)-compliant infrastructure are essential for maintaining quality and integrity of drugs throughout the supply chain.³

DHL’s expanded network seeks to reduce dependence on commercial carriers by providing consistent, controllable capacity for cold-chain airfreight. This approach can enhance supply chain resilience amid ongoing capacity constraints, geopolitical tensions, and regulatory complexity facing global pharma manufacturers and healthcare providers. According to the company release,¹ the expanded global network will initially connect Brussels and Cincinnati, facilitating direct temperature-controlled transport between major European and Midwest US hubs.

What infrastructure enhancements are included?

The addition of a Boeing 777 freighter, branded under DHL Health Logistics, underscores the emphasis on consistent capacity and thermal integrity. Dedicated aircraft capacity can minimize handling events and temperature variation, critical for biologics and cell and gene therapies. The Brussels–Cincinnati corridor is complemented by a deep temperature-controlled facility at BRUcargo, which boasts extensive GDP-compliant storage, enhancing integration with global LSH supply routes.

The expanded network includes more than 30 GDP-compliant aviation hubs and gateways, intended to provide pharma clients with end-to-end visibility and quality control across long-haul transport lanes. Enhanced infrastructure seeks to reduce reliance on heavy passive packaging and costly refrigerated containers by leveraging purpose-built facilities and logistics processes tailored to healthcare products.

How does this expansion fit broader industry trends?

The expansion aligns with DHL’s multi-year investment strategy to build a resilient, globally integrated healthcare logistics platform. In 2025, DHL announced a $2.35 billion (€2 billion) investment² to enhance life sciences and healthcare logistics capabilities, targeting GDP-certified pharma hubs, multi-temperature lanes, new temperature-controlled vehicles, and advanced IT systems for end-to-end visibility and compliance.

"Life sciences and healthcare companies expect cold chain solutions that are reliable, compliant, and transparent from end to end - and those expectations are rising fast," commented Oscar de Bok, CEO of DHL Global Forwarding, Freight, in a company press release.¹ "At the same time, they're looking for ways to simplify supply chains and reduce costs. Our expanded network brings together DHL Aviation's global air connectivity, our GDP-compliant station network, and our major investments in modern, temperature-controlled facilities. The result is a more resilient, more efficient logistics backbone for customers who depend on flawless quality to deliver critical therapies to patients."

For supply chain professionals, the DHL expansion illustrates how logistics service providers are investing in dedicated infrastructure to support healthcare customers, underscoring the importance of temperature control, streamlined routing, and compliance in complex global distribution networks.

References

1. DHL Group expands Airfreight Cold Chain Network to advance global health logistics. DHL Group. Published February 19, 2026. Accessed February 19, 2026. https://group.dhl.com/en/media-relations/press-releases/2026/dhl-group-expands-airfreight-cold-chain-network-to-advance-global-health-logistics.html

2. DHL Group to invest EUR 2 billion by 2030 in DHL health logistics to boost globally integrated healthcare solutions. DHL Group. Published April 7, 2025. Accessed February 19, 2026. https://group.dhl.com/en/media-relations/press-releases/2025/dhl-group-to-invest-2-billion-in-dhl-health-logistics.html

3. Good distribution practice. European Medicines Agency. Accessed February 19, 2026. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/compliance-post-authorisation/good-distribution-practice